Alpha Tau Medical (NASDAQ:DRTS - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $16.00 price target on the stock. HC Wainwright's target price indicates a potential upside of 33.67% from the stock's current price.
A number of other equities analysts have also weighed in on DRTS. Barclays upped their target price on Alpha Tau Medical from $17.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, September 3rd. Benchmark reissued a "buy" rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Zacks Research upgraded shares of Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Monday, November 9th. Piper Sandler upgraded shares of Alpha Tau Medical from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $8.00 to $22.00 in a research note on Wednesday, November 11th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Alpha Tau Medical in a report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.20.
Check Out Our Latest Analysis on Alpha Tau Medical
Alpha Tau Medical Stock Down 10.5%
Shares of NASDAQ:DRTS opened at $11.97 on Tuesday. The business's 50 day simple moving average is $14.00 and its two-hundred day simple moving average is $10.94. The firm has a market cap of $1.08 billion, a P/E ratio of -11.51 and a beta of 1.28. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09. Alpha Tau Medical has a 52-week low of $3.43 and a 52-week high of $15.79.
Insider Transactions at Alpha Tau Medical
In other Alpha Tau Medical news, CFO Raphi Levy sold 2,871 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $15.00, for a total transaction of $43,065.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company's stock, valued at approximately $1,352,700. The trade was a 3.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 39.50% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Everhart Financial Group Inc. bought a new position in shares of Alpha Tau Medical in the second quarter valued at approximately $126,000. Principal Financial Group Inc. bought a new stake in Alpha Tau Medical during the first quarter worth $132,000. Finally, Renaissance Technologies LLC bought a new stake in Alpha Tau Medical during the first quarter worth $286,000. Institutional investors own 2.65% of the company's stock.
Alpha Tau Medical Company Profile
(
Get Free Report)
Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.